Future of Pharmaceutical CDMO Market | Biologics Manufacturing, AI Integration & Global Expansion | Future of Pharmaceutical CDMO Market | Biologics Manufacturing, AI Integration & Global Expansion

DataM Intelligence has released a new research report titled "Pharmaceutical Contract Development and Manufacturing Market Size 2026" The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the global Pharmaceutical Contract Development and Manufacturing market.

Ready to scale in the Pharmaceutical Contract Development and Manufacturing Market? Connect with the right partners and unlock new growth opportunities today:- https://www.datamintelligence.com/partner-identification-enquiry/pharmaceutical-contract-development-and-manufacturing-market?rs

Partner Identification

✓Increase Your Customer Base by 3X using our Partner Identification tool
✓Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
✓Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
✓Prioritize partners by strategic fit rather than general capability.

United States: Recent Industry Developments

✅ March 2026: Catalent Inc. expanded its biologics manufacturing capabilities, focusing on advanced cell and gene therapy services to meet rising demand for personalized medicines.

✅ February 2026: Lonza Group enhanced its large-scale mammalian manufacturing facilities in the U.S. to support increasing global demand for biologics and biosimilars.

✅ January 2026: Thermo Fisher Scientific introduced integrated end-to-end CDMO solutions, streamlining drug development from early-stage research to commercial manufacturing.

✅ December 2025: Pfizer CentreOne invested in expanding sterile injectable manufacturing capacity to address growing demand for complex injectable drugs.

Download Free Sample Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/pharmaceutical-contract-development-and-manufacturing-market?rs

List of Key Players 2026:

Lonza Group, Thermo Fisher Scientific Inc., Catalent, Recipharm AB, ABBVIE, Siegfried Holding AG, Evonik Industries, Boehringer Ingelheim, Piramal Pharma Limited, Fujifilm Healthcare, Asymchem Laboratories (Tianjin) Co., Ltd., WuXi AppTec, among others.

Growth Forecast Projected 2033:

The Global Pharmaceutical Contract Development and Manufacturing Market is anticipated to rise at a considerable rate during the forecast period, between 2026 and 2033. In 2025, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Key Developments 2025-2026:

✅ February 2026: Leading CDMOs expanded biologics manufacturing capacity, particularly for monoclonal antibodies and cell & gene therapies, to address rising global demand and pipeline growth.

✅ January 2026: Contract manufacturers introduced advanced continuous manufacturing and AI-driven process optimization technologies to enhance efficiency, reduce costs, and accelerate time-to-market.

✅ December 2025: Adoption of integrated end-to-end CDMO services increased, with pharmaceutical companies outsourcing drug development, clinical trials, and commercial manufacturing to streamline operations.

✅ November 2025: Companies strengthened global footprints by expanding facilities in Asia-Pacific and North America to support growing demand from emerging biotech firms and large pharma clients.

✅ October 2025: Investments in high-potency API (HPAPI) manufacturing and sterile fill-finish capabilities improved safety standards, compliance, and production scalability for complex therapeutics.

How Our Market Research Process Works:

The global Pharmaceutical Contract Development and Manufacturing Market research report is developed using a comprehensive combination of primary and secondary data sources. The study evaluates a wide range of industry-influencing factors, including government regulations, evolving market dynamics, competitive intensity, and historical performance trends. It also analyzes technological advancements, emerging innovations, and developments across related industries. In addition, the report assesses market volatility, growth opportunities, potential barriers, and key challenges that could impact the future expansion of the Pharmaceutical Contract Development and Manufacturing ecosystem.

Recent Mergers & Acquisitions (M & A) 2025-2026:

✅ January 2026: Siegfried Holding AG agreed to acquire multiple drug substance manufacturing sites in the U.S. and Australia to expand CDMO capacity.

✅ January 2026: Zydus Lifesciences acquired biologics manufacturing facilities from Agenus Inc. to strengthen its CDMO business (Zylidac Bio).

✅ January 2026: ESTEVE acquired TerSera Therapeutics infusion business unit to expand specialty manufacturing and U.S. footprint.
Request Strategic Market Customization: https://datamintelligence.com/customize/pharmaceutical-contract-development-and-manufacturing-market?rs

Japan: Recent Industry Developments

✅ March 2026: Fujifilm Diosynth Biotechnologies expanded its biologics production network, focusing on advanced therapies including monoclonal antibodies and gene therapies.

✅ February 2026: AGC Biologics strengthened its global cell therapy manufacturing footprint with new process development capabilities.

✅ January 2026: Takeda Pharmaceutical Company increased outsourcing partnerships to accelerate clinical-stage drug development and improve production scalability.

✅ December 2025: Astellas Pharma invested in expanding contract manufacturing collaborations for innovative oncology and specialty drug pipelines.

Major Focused Key Segmentations 2026:

By Service
The pharmaceutical contract services market is segmented by service into pharmaceutical manufacturing services, drug development services, and biologics manufacturing services. Pharmaceutical manufacturing services account for a significant share, as companies increasingly outsource production to reduce costs, improve efficiency, and focus on core competencies. Drug development services are also critical, supporting activities such as preclinical research, clinical trials, and regulatory approvals, thereby accelerating time-to-market for new therapies. Biologics manufacturing services are witnessing rapid growth due to the rising demand for complex biologic drugs, including monoclonal antibodies and vaccines, which require specialized production capabilities and advanced technologies.

By End-User
Based on end-user, the market is categorized into large pharmaceutical companies, small and mid-sized pharmaceutical companies, generic pharmaceutical companies, and others. Large pharmaceutical companies dominate the segment due to their extensive R&D pipelines and frequent outsourcing of manufacturing and development activities to enhance scalability and efficiency. Small and mid-sized pharmaceutical companies increasingly rely on contract service providers to access advanced technologies and expertise without heavy capital investment. Generic pharmaceutical companies also represent a significant segment, driven by the need for cost-effective manufacturing and faster production timelines. The "others" category includes biotechnology firms and research organizations, which further contribute to market demand through innovation and specialized service requirements.

Regional Growth Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

We Provide Benefits of the Report:

Chapter 1: Lays the foundation by defining the scope of the report, highlighting core market segments across regions, product types, and applications. It delivers a clear snapshot of current market size, growth potential, and how the industry is expected to evolve in both the near and long term.

Chapter 2: Spotlights the most impactful market insights, unveiling the transformative trends and forces shaping the future of the industry.

Chapter 3: Provides a deep dive into the competitive landscape of , covering revenue shares, strategic initiatives, and notable mergers & acquisitions that are reshaping the market.

Chapter 4: Presents detailed company profiles of leading players featuring financial performance, product portfolios, profit margins, and key milestones that set them apart in the industry.

Chapters 5 & 6: Break down revenue analysis at both regional and country levels, offering precise data on market size, growth drivers, and expansion opportunities across global markets.

Chapter 7: Analyzes the market by product type, spotlighting segment-specific opportunities and helping stakeholders identify untapped, high-growth areas.

Chapter 8 :Explores the market through application-based segmentation, assessing demand across industries and pinpointing downstream sectors with the strongest potential for growth.

Chapter 9: Maps the industry's supply chain in detail, tracing upstream and downstream activities to provide clarity on value creation across the ecosystem.

Chapter 10: Wraps up with a concise summary of the report's key insights distilling the most critical findings and strategic takeaways for decision-makers and stakeholders.

Unlock Full 360° Strategic Report: https://www.datamintelligence.com/buy-now-page?report=pharmaceutical-contract-development-and-manufacturing-market?rs

Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/pharmaceutical-contract-development-and-manufacturing-subscription?rs

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.